Cindy A Sprecher

This inventor holds 65 USPTO granted patents and 18 published patent applications, plus 5 CIPO patents and 10 EPO patents, primarily in Cytokine Receptors (CPC class 5303). Top assignees: Zymogenetics, Inc., The University of New Mexico, Novo Nordisk A/s. Active years: 1995-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Cindy A Sprecher. Retrieved from https://idiyas.com/inventor/cindy-a-sprecher

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 65 (Patent Applications = 18)

% Patents Active = 47.7

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 10 (Patent Applications = 8)

Average Co-Inventor Count = 4.6

ph-index = 21

Forward Citations = 1,149(Granted Patents)

Forward Citations (Not Self Cited) = 1,029(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Seattle, WA (US) (1995 - 2012)
Patagonia, AZ (US) (2006 - 2012)
Hereford, AR (US) (2014)
Hereford, AZ (US) (2009 - 2017)
Sierra Vista, AZ (US) (2006 - 2019)

Company Filing History:

The University of New Mexico

5. 3 out of 834,659

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2019

Loading Chart...

Areas of Expertise:

Cytokine Receptor

ZCYTOR17

Zalpha11 Ligand

Antibodies

Polynucleotides

Hematopoietic Cells

Inflammatory Disease

Atopic Dermatitis

Fusion Proteins

Soluble Receptors

Ligand Antibodies

Cytokine Ligands

65 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10227415 - Methods of producing a zcytor17 heterodimeric cytokine receptor (2019-03-12),

2. 9738700 - ZCYTOR17 heterodimeric cytokine receptor (2017-08-22),

3. 9605062 - Polynucleotides encoding ZCYTOR17 ligand antibodies (2017-03-28),

4. 9212213 - ZCYTOR17 heterodimeric cytokine receptor (2015-12-15),

5. 8778344 - Method of treating atopic dermatitis with antibody to zcytor17 ligand (2014-07-15),

6. 8648182 - Polynucleotides encoding antibodies to cytokine receptor zcytor17 (2014-02-11),

7. 8647866 - ZCYTOR17 heterodimeric cytokine receptor polynucleotides (2014-02-11),

8. 8383775 - Cytokine zalpha11 ligand (2013-02-26),

9. 8309692 - Antibodies to cytokine receptor ZCYTOR17 (2012-11-13),

10. 8227575 - Cytokine zalpha11 ligand antibodies (2012-07-24),

11. 8217008 - Methods of treating inflammatory disease using a soluble IL-20 receptor (2012-07-10),

12. 8124378 - Murine zcytor17 ligand polynucleotides (2012-02-28),

13. 8110180 - Method of use of cytokine ZALPHA11 ligand (2012-02-07),

14. 8017343 - Cytokine zalpha11 ligand antibodies and methods of use (2011-09-13),

15. 8013124 - Antibodies to human zcytor17 ligand (2011-09-06),

Title: **Innovative Contributions of Cindy A. Sprecher in Cytokine Research**

Introduction

Cindy A. Sprecher is a prominent inventor based in Seattle, Washington, with an impressive portfolio of 65 patents. Her work primarily focuses on the development of novel cytokine receptors that play a crucial role in hematopoietic, lymphoid, and myeloid cell proliferation and development. Sprecher's innovative approaches have significant implications in therapeutic applications for various medical conditions.

Latest Patents

Cindy A. Sprecher's latest patents revolve around the methods of producing zcytor17 heterodimeric cytokine receptors. These patents disclose novel polypeptide combinations and polynucleotides encoding these polypeptides. The inventions also cover methods and compositions related to zcytor17-containing multimeric or heterodimer cytokine receptors, which can be utilized as novel cytokine antagonists. Furthermore, her inventions allow for the detection of ligands that stimulate cell proliferation and development in vitro and in vivo. These patents also encompass methods for producing these multimeric or heterodimeric cytokine receptors, along with their respective uses and antibodies.

Career Highlights

Throughout her career, Cindy Sprecher has made significant contributions to the field of cytokine research, particularly during her tenure at Zymogenetics, Inc. Her extensive work has positioned her as a leading figure in the development of cytokine-based therapies, showcasing her ability to innovate within the realms of biotechnology and pharmaceuticals.

Collaborations

Cindy has collaborated with notable professionals such as Donald C. Foster and Angela K. Hammond. These partnerships have enriched her research endeavors, allowing for a comprehensive approach to understanding and developing cytokine-related treatments.

Conclusion

With 65 patents to her name, Cindy A. Sprecher is a distinguished inventor whose contributions to cytokine research hold great promise for advancing therapeutic methodologies. Her innovative solutions and collaborative efforts continue to influence the medical field profoundly, solidifying her legacy as a pioneer in biotechnology.

Profile summary based on public USPTO records.